London, May 2, 2026, 23:01 (BST)
- Haleon PLC counted 8.879 billion ordinary shares carrying voting rights as of April 30, now serving as the updated figure for UK disclosure purposes.
- The update drops in the middle of a £500 million buyback programme slated to run through 2026. So far, according to the first-quarter statement, roughly 36% is done.
- Investors are eyeing the capital return while grappling with sluggish first-quarter sales growth, higher freight expenses, and the prospect of a North America recovery.
Haleon PLC reported 8,879,691,798 total ordinary shares with voting rights as of April 30, handing investors the key number they’ll need if a stake crosses a disclosure threshold.
It’s a modest update, but not without significance. Haleon, which owns Sensodyne, Panadol and Advil and trades in London, is leaning on buybacks to slim down its capital base, while it argues that the softness seen in the first quarter was down to seasonality. The latest filing pegs treasury shares—the stock it holds on its own books, with no voting rights—at 12,240,797.
The latest voting-rights count landed roughly 11.4 million shares short of what was registered for the April 24 annual meeting record date, when Haleon listed 8,891,124,301 total voting rights. At that same meeting, investors signed off on a plan authorizing the company to buy back its own stock.
Haleon put £500 million on the table for share buybacks in 2026, and, according to its first-quarter trading statement, about 36% of that program has already gone through. Cancelled shares shrink the overall share count, or they might get tucked away in treasury for future use.
Haleon’s first-quarter figures landed with some bumps. Revenue reached £2.86 billion, but organic revenue growth was just 2.2%—that’s sales stripped of currency swings, deals, and a few supply contracts. Price edged up 2.4%, while volumes slipped 0.2%.
This all lands as Haleon tries to persuade investors that growth is set to pick up. Management stuck to its 2026 targets: organic revenue up 3% to 5%, and adjusted operating profit—excluding currency swings—still expected to climb at a high-single-digit pace.
Chief Executive Brian McNamara pointed to signs of “North America returning to growth” for Haleon, and said he expects “growth to accelerate” as the year goes on—even while acknowledging the ongoing uncertainty in the global geopolitical and macroeconomic environment. The company’s biggest market, North America, delivered 1.0% organic growth for the quarter, driven by gains from Sensodyne and parodontax. Haleon Corporate
This isn’t just about Haleon. Reuters flagged that consumer names like Procter & Gamble and Reckitt have also been squeezed by pricier energy and shipping. For Reckitt, softer demand for cold and flu remedies was another drag on its quarter. Haleon, which counts Theraflu and Robitussin among its brands, gets hit too when the cold and flu season underwhelms.
Haleon is already feeling the pinch from “surcharges on freight,” finance chief Dawn Allen said, adding that those costs will likely climb. Most of the company’s contracts and hedges are locked in at fixed prices through the end of the year. Pricing adjustments could come where possible, McNamara told analysts, according to Reuters. Reuters
Buybacks aren’t a fix for softening demand. Haleon blamed a mild cold and flu season for shaving roughly 130 basis points off its first-quarter organic growth. Reuters added that consumer spending in the Middle East—about 5% of Haleon’s revenue—fell by a low-double-digit percentage.
Quilter’s Chris Beckett didn’t mince words in a note to Reuters, saying Haleon “needs more than the toothpaste business to start performing.” Oral Health posted an 8.3% organic jump for the quarter, while Respiratory Health slid 3.4%. Reuters
On May 1, Haleon shares ended at 344.10 pence in London, climbing 1.21% for the day. Earlier in the week, the stock lost ground after the company pointed to cost pressures and a slowdown in first-quarter sales growth.
